Apposite

• 2 April 2008
  Apposite Capital Appoints Valerie Auffray as Investor Relations Manager
• 20 March 2008
  David Porter, Managing Partner of Apposite Capital LLP, provides his views on single sector funds to Real Deals magazine

Ambrx

• February 26, 2008
  Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
• December 18, 2007
  Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
• December 17, 2007
  Ambrx Announces Drug Discovery Alliance with Eli Lilly and Company
• July 24, 2007
  Ambrx Appoints Stephen Kaldor Chief Executive Officer
• June 19, 2007
  Merck Serono and Ambrx to Collaborate on Development of Next Generation Growth Hormone Products
• February 12, 2007
  Ambrx Initiates Phase I/II Clinical Trial of Novel Human Growth Hormone Product Candidate
• August 14, 2006
  Ambrx Receives Additional U.S. Patent Covering ReCODE™ Technology
• July 24, 2006
  Ambrx Secures Additional $3 Million in Series C Financing
• July 19, 2006
  Ambrx Names Kevin L. Eastwood Vice President, Corporate Development
• July 05, 2006
  Ambrx Secures $52 Million in Series C Financing

Serentis

• Serentis appoints Peter Keen as new Corporate Development and Finance Director
• Serentis acquires atopic dermatitus company Surface Therapeutics
• Serentis Raises £10.3 Million Series A Financing

Pharmakodex

• Pharmakodex – Chairman Appointment – 12th July 2007
• Pharmakodex Financing release – 16th Nov 2006

CancerPartnersUK

• The Cancer Reform Strategy challenges, choices and opportunities.
• Article by Professor Karol Sikora – Personalised medicine for cancer: from molecular signature to therapeutic choice.
• Article by Professor Karol Sikora – Cancer. The Next Ten years.
• 27.08.06 – CancerPartnersUK Press Release.

Ambit

• Ambit Biosciences raises over $49 million in Series D Financing